Beyond Alcohol: India's MASLD Epidemic Sweeps Millions, Especially the Young

India is currently grappling with a silent, widespread liver epidemic, Metabolic dysfunction-associated steatotic liver disease (MASLD), which now affects over 100 million adults. This condition, previously known as non-alcoholic fatty liver disease (NAFLD) until a global name change in 2023, is no longer just an adult problem; doctors are increasingly diagnosing it in young Indians and even children, raising alarms about a looming public health crisis. It's a stealthy disease, often showing no symptoms until serious liver damage has already occurred, meaning many are living with it undiagnosed. The surge in MASLD cases is deeply tied to India's rapidly changing lifestyle, marked by rising rates of Type 2 Diabetes Mellitus, obesity, high blood pressure, and sedentary habits. What's particularly concerning is the prevalence of 'lean MASLD,' where individuals with normal body weight still develop the disease due to hidden fat around organs and insulin resistance, challenging traditional notions that link liver disease solely to heavy drinking or visible obesity. Experts warn that the consequences, including liver failure and cancer, could manifest 20-30 years down the line, placing immense pressure on future healthcare infrastructure. Recognizing this urgent threat, the Indian government has incorporated MASLD into its National Programme for Prevention and Control of Non-communicable Disease (NP-NCD) since 2023, emphasizing early detection. Health officials are now pushing for comprehensive awareness campaigns, integration of liver checks into routine care for high-risk groups, and wider availability of non-invasive screening tools like FibroScan. While lifestyle changes remain the cornerstone, new medications like Saroglitazar, Resmetirom, and Semaglutide are emerging as complementary treatments, highlighting the critical need for early diagnosis to prevent irreversible liver damage and a national health catastrophe.